GSK 568859

Drug Profile

GSK 568859

Alternative Names: 568859; GSK568859; SB-568859

Latest Information Update: 19 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer GlaxoSmithKline
  • Class Cardiovascular therapies
  • Mechanism of Action 1-alkyl-2-acetylglycerophosphocholine esterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atherosclerosis

Most Recent Events

  • 19 Apr 2011 Discontinued - Phase-I for Atherosclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top